A perspective on incentives for novel inpatient antibiotics: No One-Size-Fits-All

Journal of Law, Medicine and Ethics

Volumn 46, Issue , 2018, Pages 59-65

  Bhatti, Taimur ^a   Lum, Ka ^b   Holland, Silas ^c   Sassman, Stephanie ^d   Findlay, David ^e   Outterson, Kevin ^f  

^a UNIVERSITY OF TORONTO   (Canada)

^b University of Pretoria ^*  (United States)

^c UNIVERSITY OF PRETORIA   (South Africa)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^e BRADFORD UNIVERSITY SCHOOL OF MANAGEMENT   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; DRUG DEVELOPMENT; ECONOMICS; HUMAN; INVESTMENT; MEDICAL RESEARCH; MOTIVATION; RISK MANAGEMENT;

ANTI-BACTERIAL AGENTS; BIOMEDICAL RESEARCH; DRUG DISCOVERY; DRUG RESISTANCE, MICROBIAL; HUMANS; INVESTMENTS; MOTIVATION; RISK SHARING, FINANCIAL;

EID: 85055918343     PISSN: 10731105     EISSN: 1748720X     Source Type: Journal    
DOI: 10.1177/1073110518782916     Document Type: Article

References (24)

1. Renwick, M. J., Brogan, D. M., Mossialos, E., “A Systematic Review and Critical Assessment of Incentive Strategies for Discovery and Development of Novel Antibiotics,” Journal of Antibiotics 69 (2016): 73-88j.
2. Pew Charitable Trust, “Antibiotics Currently in Clinical Development,” updated 2017, available at (last visited March 22, 2018).
3. Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance, January 2016, available at (last visited March 22, 2018)
4. Industry Roadmap for Progress on Combating Antimicrobial Resistance, September 2016, available at (last visited August 15, 2017).
5. Silver, L. L., “Challenges of Antibacterial Discovery,” Clinical Microbiology Reviews 24, no. 1 (2011): 71-109.
6. Rex, J. H., Goldberger, M., Eisenstein, B. I., Harney, C., “The Evolution of the Regulatory Framework for Antibacterial Agents, ” Annals of the New York Academy of Science 1323 (2014): 11-21.
7. DRIVE-AB Final Report, “Revitalizing the Antibiotic Pipeline: Stimulating Innovation While Driving Sustainable Use and Global Access,” at 27-28, 2018, available at (March 22, 2018).
8. Sommer, M. O. A., Munck, C., Toft-Kehler, R.V., Andersson, D. I., “Prediction of Antibiotic Resistance: Time for a New Preclinical Paradigm?” Nature Reviews Microbiology 15 (2017): 689-696.
9. Kinch, M. S., “ An Overview of FDA-Approved Biologics Medicines, ” Drug Discovery Today 20, no. 4 (2015): 393-398.
10. Review on Antimicrobial Resistance: Chaired by O'Neil, Jim, Securing New Drugs for Future Generations: The Pipeline of Antibiotics, May 2015, available at (last visited March 22, 2018).
11. Outterson, K., New Business Models for Sustainable Antibiotics, 2014, available at (last visited March 22, 2018).
12. Chorzelski, S.., Breaking through the Wall: Enhancing Research and Development of Antibiotics in Science and Industry, Global Union for Antibiotic Research & Development Initiative (2015), available at (last visited March 22, 2018).
13. International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Policy Position: Sustainable Models to Overcome the Challenging Economics of Antimicrobial R&D, available at (last visited March 22, 2018).
14. Goldhammer, J., Mitchel, K., Parker, A., Anderson, B., Sahil, J., “The Craft of Incentive Prize Design: Lessons from the Public Sector,” 2014, available at (March 22, 2018)
15. J. H. Rex and K. Outterson, “Antibiotic Reimbursement in a Model Delinked from Sales: A Benchmark-Based Worldwide Approach,” The Lancet Infectious Diseases 16, no. 4 (2016): 500-505.
16. Daniel, G., Schneider, M., McClellan, M., “Addressing Antimicrobial Resistance and Stew-ardship: The Priority Antimicrobial Value and Entry (PAVE) Award,” JAMA 318, no. 12 (2017): 1103-1104.
17. Viale, P., Giannella, M., Lewis, R., Trecarichi, E. M., Petrosillo, N., Tumbarello, M., “Predictors of Mortality in Multidrug-Resistant Klebsiella Pneumoniae Bloodstream Infections,” BioMed Central Infectious Disease 14 (2014): 572
18. A. F. Shorr, M. D. Zilberberg, S. T. Micek, and M. H. Kollef, “Predictors of Hospital Mortality among Septic ICU Patients with Acinetobacter spp.bacteremia: A Cohort Study,” Expert Review of Anti-Infective Therapy 11, no. 10 (2013): 1053-1063
19. T. P. Lodise, N. Patel, A. Kwa, J. Graves, J. P. Furuno, E. Graf-funder, B. Lomaestro, and J. C. McGregor, “Predictors of 30-Day Mortality among Patients with Pseudomonas Aeruginosa Bloodstream Infections: Impact of Delayed Appropriate Antibiotic Selection,” Antimicrobial Agents Chemotherapy 51, no. 10 (2007): 3510-3515.
20. Kesselheim, A. S., Outterson, K., “Fighting Antibiotic Resistance: Marrying New Financial Incentives to Meeting Public Health Goals,” Health Affairs 29, no. 9 (2010): 1689-1696
21. A. Sertkaya, J. T. Eyraud, A. Birkenbach, et al., “Analytical Framework for Examining the Value of Antibacterial Products,” available at (last visited March 22, 2018).
22. DRIVE-AB, Incentives to Stimulate Antibiotic Innovation: The Preliminary Findings of DRIVE-AB, available at (last visited March 22, 2018).
23. European Commission, A European One Health Action Plan against Antimicrobial Resistance (AMR), available at (last visited March 22, 2018).
24. Schaffer, S. K., West, P., Towse, A., Henshall, C., Mestre-Ferrandiz, J., Masterton, R., Fischer, A., Assessing the Value of New Antibiotics: Additional Elements of Value for Health Technology Assessment Decisions, Office of Health Economics, May 2017, available at (last visited March 22, 2018).